港股異動 | 歐舒丹逆勢大漲超9% 3日累計反彈17% 機構指估值具吸引力
格隆匯3月19日丨歐舒丹(0973.HK)午後股價逆勢上漲,現漲幅擴大至9.15%,報12.64港元,暫成交1106萬港元,最新總市值186.68億港元。近期股價累跌創下歷史新低10.02港元,現連續3日反彈,累升17%。花旗發表研究報告指出,歐舒丹股價創歷史新低後,估值具吸引力,因此將其投資評級由“中性”上調至“買入”,但將目標價調低33%至13.6港元,即便如此,對於現價仍有漲幅空間。公司資產負債狀況穩健,淨槓桿率為40%。值得注意的是,日前貝恩公司聯合阿里巴巴天貓日前發佈疫情期間的銷售報告顯示,在疫情期間美粧品類銷售額整體下降30%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.